Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.

Abstract: The present invention provides, among other things, dimeric multispecific binding agents (e.g., fusion proteins comprising antibody components) that have improved properties over multispecific binding agents without the capability of dimerization.

Abstract: Antigen-binding proteins specific for HLA-A2-restricted Wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv (scFv) fragments, as well as chimeric antigen receptors. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the antigen-binding proteins are provided. Methods of using the antigen-binding proteins in the treatment of hyperproliferative diseases such as cancer are also disclosed.

Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.

Abstract: In this application are described high affinity anti-GD2 antibody agents, and various methods and reagents related thereto, including for example for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.

Abstract: In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.

Abstract: A vehicle door includes a door body, a window panel, a window regulator rail and a lifter plate. The door body defines a window opening and a window panel is slidably supported in the door body. The window regulator rail is mounted to the vehicle frame and the lifter plate is slidably coupled to the window regulator rail for up and down sliding movement along the window regulator rail. The lifter plate includes a window glass support portion supporting a lower edge of a window panel and a water deflecting structure that is configured and arranged to deflect water running down the window panel away from the window regulator rail.

Abstract: A vehicle door includes a door body, a window panel, a window regulator rail and a lifter plate. The door body defines a window opening and a window panel is slidably supported in the door body. The window regulator rail is mounted to the vehicle frame and the lifter plate is slidably coupled to the window regulator rail for up and down sliding movement along the window regulator rail. The lifter plate includes a window glass support portion supporting a lower edge of a window panel and a water deflecting structure that is configured and arranged to deflect water running down the window panel away from the window regulator rail.